- Sanofi India’s net income was 1.37 billion rupees, marking a decrease of 28% year-on-year.
- The net income was below the estimated 1.49 billion rupees.
- Sanofi India’s revenue was 7.32 billion rupees, a small decrease of 0.7% from the previous year.
- This revenue also fell short of the estimated revenue of 7.61 billion rupees.
- The company reported other income of 65 million rupees, which is a drastic decrease of 75% compared to last year.
- Sanofi India’s total costs increased by 1.4% from the previous year, reaching 5.24 billion rupees.
- Sanofi India’s stock currently stands with 6 buys, 0 holds, and 1 sell according to the latest data.
A look at Sanofi Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sanofi, a prominent pharmaceutical company, seems to be positioned well for long-term success based on its Smartkarma Smart Scores. With a solid Dividend score of 4 and a strong Momentum score of 4, Sanofi appears to offer stable returns to investors and a positive growth trajectory. Additionally, the company scores well in Resilience, indicating its ability to weather uncertainties. While Value and Growth scores are moderate at 3, Sanofi‘s diverse portfolio of prescription pharmaceuticals, vaccines, and various medicines across different therapeutic areas positions it as a reliable player in the global healthcare market.
Sanofi‘s overall outlook appears promising, especially with above-average scores in Dividend, Resilience, and Momentum. With its focus on developing essential medications for cardiovascular, thrombosis, metabolic disorders, central nervous system, and oncology, Sanofi‘s commitment to innovation and addressing critical health needs worldwide sets a strong foundation for its long-term performance in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
